Avicanna Hosts Symposium on Cannabinoid-based Medicine - Seite 2

Womens’ College Hospital
  Erin Prosk
Sante Cannabis
              Dr. Julia Hoeng 
Vectura Fertin Pharma
  Keith Stratchan
MediPharm Labs Corp.
              Dr. Evan Lewis
Neurology Centre of Toronto
         

The event will also highlight necessary education and resources for Health Care Providers seeking to implement medical cannabis as a potential treatment option including the Company’s Avicenna Academy. Avicanna’s team will also be presenting advancements in cannabinoid-based research including the Company’s recently completed research studies in addition to introducing to the MyMedi.ca medical cannabis care platform.  

“We feel privileged to bring together clinicians and thought leaders with direct experience in prescribing cannabinoid-based medicine and medical cannabis to patients. Our aim is to increase discussion and further explore possibilities around cannabinoid-based medicine’s potential as a treatment option for HCPs” stated Dr. Karolina Urban, Executive Vice President of Medical Affairs at Avicanna. 

To register for the symposium: 

Health care practitioners and researchers, may apply for registration at: www.avicanna.com/symposium 

About Avicanna Inc. 

Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development that has led to the commercialization of more than thirty products across various market segments: 

• Medical Cannabis & Wellness Products (RHO Phyto): The formulary offers a diverse range of proprietary formulations including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids and is supported with ongoing patient, and medical community education. RHO Phyto has been established as a leading medical brand in Canada and is currently available nationwide to patients across several medical channels and continues to expand into new international markets.